One of the Triangle's most experienced pharmaceutical industry executives will join Elan Corp. as chairman of the Irish biotechnology company's board.
Robert Ingram has joined Elan's board and will replace Kyran McLaughlin as chairman on Jan. 26, the company announced this morning.
"I look forward to working with the Board and the management team to deliver long term benefits to science, patients and shareholders," Ingram said in a prepared statement.
Ingram was CEO of Glaxo and later vice chairman of GlaxoSmithKline. Since January, Ingram also has worked as an advisor to GSK Chief Executive Andrew Witty. The British pharmaceutical giant has its North American headquarters in Research Triangle Park.
Ingram, who turns 68 today, was traveling and didn't return calls seeking comment.